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Summary: Highly active antiretroviral therapy (HAART) has proved efficient in increasing CD4
counts in many randomized clinical trials. Because randomized trials have some limitations (e.g.,
short duration, highly selected subjects), it is interesting to assess it using observational studies.
This is challenging because treatment is started preferentially in subjects with severe conditions, in
particular in subjects with low CD4 counts. This general problem had been treated using Marginal
Structural Models (MSM) relying on the counterfactual formulation. Another approach to causality
is based on dynamical models. First, we present three discrete-time dynamic models based on linear
increments (LIM): the simplest model is described by one difference equation for CD4 counts; the
second has an equilibrium point; the third model is based on a system of two difference equations
which allows jointly modeling CD4 counts and viral load. Then we consider continuous time models
based on ordinary differential equations with random effects (ODE-NLME). These mechanistic
models allow incorporating biological knowledge when available, which leads to increased power for
detecting treatment effect. Inference in ODE-NLME models, however, is challenging from a numerical
point of view, and requires specific methods and softwares. LIMs are a valuable intermediary
option in terms of consistency, precision and complexity. The different approaches are compared
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in simulation and applied to HIV cohorts (the ANRS CO3 Aquitaine Cohort and the Swiss HIV
Cohort Study).
Key words: Causality; Dynamic models; HAART; Linear Increment Models (LIM); Marginal
Structural Models (MSM); Mechanistic models; Non Linear Mixed Effect Models (NLME); Obser-
vational study; ODE-NLME; Ordinary Differential Equation (ODE), Treatment effect.
c© 2015 The Society for the Study of Evolution. All rights reserved.
Dynamic models for estimating the effect of HAART on CD4 in observational studies 1
1. Introduction
Assessing the effect of a treatment in observational studies is useful because randomized
clinical trials often have short durations and include highly selected subjects. This is chal-
lenging because the treatment may change, and covariates history of a subject up to time t
may influence treatment given after t, and may also influence the outcome of interest, which
induces a time-dependent confounding. For instance, one may wish to assess the effect of
antiretroviral therapy in HIV infected subjects. As CD4+ T-lymphocytes (CD4, in short)
are the main target cells of the HIV virus, it is possible to assess the effect of a treatment on
the blood concentration of these cells: CD4 counts are measurements of this concentration.
In observational studies, however, the decision to start an antiretroviral therapy may depend
on CD4 counts as well as on other covariates. In this setting, it has been demonstrated
that a conventional regression analysis leads to biased estimates of the treatment effect,
typically underestimating it, and possibly (wrongly) indicating a negative effect. This is
called “confounding by indication” (Walker, 1996).
The marginal structural models (MSM) (Robins et al., 2000) have been proposed for
treating this problem; this is based on choosing a causal model in terms of potential responses
(which are often counterfactual) to the different treatment histories. The parameters of a
MSM can be estimated through a weighted approach but other methods exist (Petersen et al.,
2006). The weights are the inverse probability (IP) of treatment attribution and are obtained
through a “treatment model” which includes the covariates linked to the outcome. Because
data are correlated, we use an IP weighted generalized estimating equation (GEE). This
approach has been applied by Herna´n et al. (2002) and by Cole et al. (2005) for estimating
the effect of zidovudine and of highly active antiretroviral therapy (HAART) on CD4 count.
Cole et al. (2007), Sterne et al. (2005) and Cole et al. (2010) used it for estimating the effect
of HAART on viral load and on AIDS or death.
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An alternative approach which does not use the potential responses representation is to use
dynamic models. The dynamic approach to causality has been pioneered by Granger (1969),
Aalen (1987), and further developed by Didelez (2008), Commenges and Ge´gout-Petit (2009),
Ge´gout-Petit and Commenges (2010) and Eichler and Didelez (2010). Assumptions needed
for a causal interpretation of dynamic models have been presented in Arjas and Parner
(2004) and Commenges and Ge´gout-Petit (2015). Dynamical models in discrete time, and
in particular Linear Increment models (LIM), have been proposed by Diggle et al. (2007)
and Hoff et al. (2015); Aalen et al. (2012) have suggested that such models can be useful for
studying HAART effect on CD4 counts or viral load. Discrete-time models, however, may
not be completely satisfactory because the processes of interest most often live in continuous
time. Systems of differential equations in continuous time can also be used to model the
interaction between HIV and CD4 cells populations. Models based on differential equations,
called “mechanistic”, considerably helped in understanding some important features of the
infection: see Perelson (2002) for a review. In our setting, it is possible to model the treatment
effect from a biological perspective. Introducing random effects allows analyzing a sample
of subjects with different parameter values without too much increasing the number of
parameters (Wu, 2005; Guedj et al., 2007; Lavielle et al., 2011). Up to now, mechanistic
models have been used to analyze data from clinical trials. Using mechanistic models to
estimate the effect of HAART based on data of large observational cohorts is a possibility,
that to our knowledge has never been attempted.
The aim of this paper is to propose dynamic models in discrete and continuous time for
assessing the causal effect of a treatment on a marker in observational studies. Specifically,
we aim at estimating HAART effect in HIV infected patients. We present several possible
dynamic models, as well as MSM models, and compare them using simulations and real
data. In Section 2, we present the statistical models: the naive model, the MSM models, the
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discrete-time dynamic models and a mechanistic model. In Section 3, we compare the results
of these models in simulation, where the data are generated from a complex mechanistic
model. Section 4 is the application on the data of two cohorts of HIV infected patients: the
Swiss HIV Cohort Study (SHCS) and the ANRS CO3 Aquitaine cohort. Section 5 concludes.
2. Modeling the treatment effect in observational studies
2.1 Notations and the naive model
We denote the value of a physiological marker Y for subject i at time t by Y it . In this
section we omit the superscript i for simplicity. The value of a treatment given at time t
is denoted by At. For sake of simplicity, we only model two treatment states: At = 0 when
treatment is not given, and At = 1 when treatment is given at time t, and we assume that
once initiated, the treatment is not interrupted; generalization to different treatment levels
is possible. If treatment is started at time t then At = 1 and At−1 = 0. In our application Yt
is the CD4 counts, At is treatment (HAART) attribution which is binary. We use overbars
to represent histories of the processes: for instance A¯t = (A0, A1, . . . , At). We denote by
cum(A¯t) the cumulative time under treatment until time t. Since A is binary we can write
cum(A¯t) =
∑t
k=1 Ak
In the absence of confounding by indication, a regression of Yt on the history of treatment
would give the effect of treatment on the marker. The simplest model would be to regress Yt
on cum(A¯t−1). It has been noted however that a piecewise linear regression model allowing
a change of treatment effect after one year was better suited (Cole et al., 2005). Thus, the
naive model that we consider is our Model 1:
E(Yt|A¯t−1) = β0 + β1cum(A¯t−1) + β2cumlag(A¯t−1). (2.1)
where cumlag(A¯t) is the cumulative time under treatment up to time t minus one year:
cumlag(A¯t) = max(0, cum(A¯t) − 1) (with the convention A¯t = 0 for t < 0). The β’s are
estimated by conventional GEE (Liang and Zeger, 1986) because it is very likely that the Yt’s
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are positively correlated, and because we are interested in the population average (Hubbard
et al., 2010). A working correlation structure has to be chosen; in presence of time-varying
covariates, the independence model should be chosen, otherwise results could be biased, as
shown by Pepe and Anderson (1994). Thus an identity working correlation matrix is used
for all GEE models.
2.2 Marginal structural models (MSM)
Since treatment is given to subjects with low CD4 counts, treated subjects tend to have low
CD4 counts. Thus, the true value of parameter β1 in Model 1 cannot be interpreted as the
causal effect. The MSM have been designed to estimate the causal effect of a treatment in
such a case. It is assumed that to each particular value a¯t of A¯t, a potential outcome Y¯t(a¯t) is
associated; a¯t can be called “treatment history” or “treatment trajectory”. This means that
if a subject had (possibly contrary to the fact) treatment trajectory a¯t, his outcome would be
Y¯t(a¯t). A model is postulated to describe how the potential outcomes vary as a function of the
different treatment trajectories. Then it has been shown that the parameters of this model,
called “causal parameters”, can be estimated with a suitably weighted GEE. The weights are
inverse-probability-of-treatment (IPT). The probability of treatment at time t depends on
the history up to time t of a vector of variables L; this history is denoted L¯t = (L0 ∈ L¯t); Lt
may include Yt itself, as well as other variables such as viral load or other biological markers
linked to the infection. The probability of treatment is estimated using a treatment model
(generally a logistic model) for each time and the weights are the product over time of these
probabilities; one often use stabilized weights as in Equation (2.3. The causal parameters
can be estimated consistently if all the confounders (factors influencing both the outcome
of interest and treatment attribution) have been taken into account. Extension to the case
with censoring has also been developed (Cole et al., 2005; Cole and Herna´n, 2008). However,
the most important correction is generally for the probability of treatment (Ko et al., 2003).
Herna´n et al. (2002) and Cole et al. (2005) proposed benchmark models also adjusting for
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confounders such as time (t) and baseline value of the biomarker (Y0) in the regression. The
model for potential outcomes that we consider is the same for our Model 2 and Model 3
(which will differ by the treatment model); it is:
E(Yt(a¯t)|a¯t−1, Y0) = β0 + β1cum(a¯t−1) + β2cumlag(a¯t−1) + β3t+ β4Y0. (2.2)
For estimating the parameters of this model, we used GEE with stabilized IPT weights
defined as:
SW (t) =
t∏
k=1
Pr(Ak = 1|A¯k−1, L0)
Pr(Ak = 1|A¯k−1, L¯k) , . (2.3)
where the probabilities at time k are estimated for every subject from logistic regressions
depending on L¯k (L0 ∈ L¯k). We tried two different treatment models. We defined the subsets
L for treatment model in Model 2 as baseline and time-varying CD4 count in class (< 200,
[200; 400],> 400) only. We extended this list for Models 3 to the main potential confounders:
viral load in categories (< 401, 401− 10000 and > 10000), and an indicator of undetectable
viral load. In Models 1, 2 and 3, the effect of treatment on CD4 counts during the first year
is given by β1 and the effect after one year of treatment is given by β1 + β2.
2.3 Discrete-time dynamical linear increment models (LIM)
When using discrete-time dynamical models, we regress the change in the marker of interest,
that is, Zit = Y
i
t −Y it−1. This fits well with a causal thinking which considers that the change
of a process depends on its present, and possibly past, state. The independence assumption
for the Zit ’s is much more acceptable than for the Y
i
t ’s. However, there remains an inter-
subject variability that we model by a random effect bi, assumed normally distributed with
zero expectation. Thus, these models specify the distribution of Zi conditional on the bi. We
propose three of these models; the simplest is Model 4:
Zit = β0 + β1A
i
t−1 + β2A
i
t−2 + bi + ε
i
t, (2.4)
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where the εit’s are i.i.d. normally distributed variables with zero expectation, and the bi’s are
normal random effects. This model can be easily fitted since this is a linear mixed-effects
model. In order to account for non equally spaced measurement of biomarkers, we extend
the notation to obtain a model which has approximately the same meaning: it is natural to
think that the change is proportional to the time elapsed between two observations, that we
note ∆it = c
i
t − cit−1, where cit is the tth calendar time of observation since baseline measure
of subject i. This extended model is obtained by redefining the increment as Zit =
Y it −Y it−1
∆it
.
In Models 4, the effect of treatment on the CD4 counts during the first year is approximated
by β1∆¯t, and the effect after one year of treatment by (β1 + β2)∆¯t, where ∆¯t is the mean of
all the ∆it.
Many deterministic dynamical models have equilibrium points; similarly many stochastic
dynamical models tend toward a stationary process: this property fits very well with the
behavior of biological systems since concentrations of many molecules or cells have a tendency
to return around the same value, a property called “homeostasis”. The difference equation
of the type Yt−Yt−1 = γ0 + γ1Yt−1 + εt corresponds to an autoregressive model of order one,
noted AR(1): Yt = γ0 + γ
′Yt−1 + εt with γ′ = (γ1 + 1). It is well known that if |γ′| < 1 this
process converges toward a stationary process (in discrete time) with expectation E(Yt) =
− γ0
1−γ′ = −γ0γ1 ; this is always defined unless γ1 = 0, as is the case in Model 4 which does
not have a finite stationary expectation. The condition amounts to −2 < γ1 < 0, and to
get a positive stationary expectation we must have β0 > 0. When using a model which has
this convergence property, it may not be necessary to have a two-slope model, so we define
Model 5 as:
Zit = β0 + β1A
i
t−1 + β2Y
i
t−1 + bi + ε
i
t. (2.5)
If −2 < β2 < 0 and β0 + β1 > 0, Y tends to a stationary process with expectation −β0+β1β2
for treated patients.
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A more realistic modeling of CD4 counts is to take viral load into account. Here, we make
a step toward mechanistic models because we know that the virus concentration and the
CD4 concentration are two inter-related processes. Thus, we propose Model 6 based on a
system of two difference equations:{
Zit = β0 + β1A
i
t−1 + β2Y
i
t−1 + β3VL
i
t−1 + bi + ε
1
it,
W it = α0 + α1A
i
t−1 + α2Y
i
t−1 + α3VL
i
t−1 + di + ε
2
it.
(2.6)
where W it =
VLit−VLit−1
∆it
, with VLit the viral load at time t, di and bi are normally distributed
independent random effects, and ε1it and ε
2
it are normal i.i.d. error variables with zero ex-
pectation. One year and subsequent years increase of CD4, as well as the long term change,
are easily computed by solving the difference equations numerically. For testing whether the
treatment has an effect, it is convenient to test the hypotheses β1 = 0 and α1 = 0, by Wald
tests for instance. As a reviewer noted, an interesting question is the correspondence between
these LIM models and MSMs. Appendix shows that under some (rather strong) assumptions,
Model 4 allows estimating the same causal parameters as Models 2-3.
2.4 Continuous Dynamical models, Mechanistic Models (ODE-NLME)
In reality, biomarkers processes live in continuous time. We use the “target cells model”
that proved to provide a good fit and to have good prediction abilities (Prague et al., 2013).
The combination of the target cells model, a model for inter-individual variability of the
parameters, and an observation model specifies our Model 7.
Biological system. We know that only infected cells (T ∗) can produce viruses (V ). The
target cells model distinguishes between uninfected quiescent cells (Q) and target cells (T ).
The instantaneous change of concentrations of these populations at time t, for all real value
of t > 0, is given by the ODE system:
dQit
dt
= λi + ρiT it − αiQit − µiQiQit,
dT it
dt
= αiQit − γiT itV it − ρiT it − µiTT it ,
dT∗it)
dt
= γiT itV
i
t − µiT∗T ∗it,
dV it
dt
= piiT ∗it − µiV V it .
(2.7)
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The system is graphically represented in Figure 1a. Here, the parameters have biological
meanings: λ is the production rate of new CD4 cells, the µ’s are death rates, α and ρ are
transition rates between quiescent and target cells, pi is the rate of production of virions
by infected cells, and γ is the infectivity parameter. The model assumes that the rate of
infection of target cells is γVt.
[Figure 1 about here.]
[Table 1 about here.]
Inter-individual variability. The model for inter-individual variability of the parameters
is a mixed-effect model for the log-transformed parameters denoted with a tilde. In this
application, based on Prague et al. (2012), two random effects uiλ and u
i
µT∗ are introduced:
λ˜i = λ˜0 + u
i
λ and µ˜
i
T ∗ = µ˜T ∗0 + u
i
µT∗ . Biologically, the causal effect of treatment can be
modeled as an effect on the infectivity parameter γ. The parameter γ consequently depends
on t through At:
γ˜i(t) = γ˜0 + βA
i
t, (2.8)
where we expect β < 0, so that the treatment decreases the infectivity of the virus.
Observation model. One important consequence of using continuous time models is
that we must distinguish between the biological system which lives in continuous time and
observations which are made at discrete time. To make an additive model for measurement
error acceptable, we use 4th-root transformation for CD4 and a log10 transformation for the
viral load respectively. Thus, the observation model is:
(Y ij )
1/4 = [Qitij + T
i
tij
+ T ∗itij ]
1/4 + ε1ij ; log10 VLij = log10 V
i
tij
+ ε2ij, (2.9)
where ε1ij and ε
2
ij are measurement errors, independently normally distributed.
Inference. Inference is much more complex and computationally demanding than in
discrete-time models; it is based on a penalized maximum likelihood approach; in order to
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avoid identifiability issues, we used a priori knowledge on mechanistic parameters: the priors
are set according to past estimates of the biological parameters in the literature (Prague et al.,
2012), and are given in Table 1. A special Newton-like algorithm has been implemented in the
NIMROD program (Prague et al., 2013). Assessing the long-term treatment effect in Model
7 is possible by analytically computing the equilibrium point. One year and subsequent years
increase of CD4 after treatment initiation can be computed by solving the ODE system for
given values of the random effects. The marginal effect can be computed as the mean of the
individual effects in the population. The infectivity parameter gives an indicator of the effect
of treatment, and a Wald test can be used to test the no-effect hypothesis “β = 0” .
3. Simulation study
We simulated composite data with the Adams et al. (2005) model, which is much more
complex than Model 7 (see Web-Supplementary Material A4): it includes two populations
of target cells and a population of immune effectors (such as cytotoxic T-lymphocytes); see
Figure 1b and Table 1. Parameters have inter-individual variability modeled by drawing
them from a normal law (with mean values listed in Table 1 and variances chosen to obtain
a variation coefficient of 50%). By controlling the value of random effects, we ensure that
the steady state baseline distributions of CD4 counts and viral load are consistent with the
baseline values distributions found in Aquitaine cohort and SHCS dataset. See Appendix A1
in Web-supplementary Material for details. We generated observations every 3 months; the
standard deviations of the measurement errors are σV L = 0.6 and σCD4 = 0.1. Viral load
was artificially made undetectable at the level of 50 copies/mL. Treatment assignment was
done by simulating a CD4 count assessment at every visit (every 3 months) and by fixing
a probability of treatment attribution depending on the observed CD4 count. We took em-
pirical probabilities from the Aquitaine cohort and SHCS dataset: treatment was attributed
in 2%, 28% or 47% of the cases if CD4 count was > 400, [400, 200] or < 200. Neither
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confounder nor drop-out was considered. We simulated n=200 and n=1500 patients. Table
3 gives a general description of both simulated and real data sets: no major inconsistency in
descriptive statistics values appears between simulated and real cohort data sets. We define
the “average causal effect in treated patients” as the mean difference between the observed
CD4 according to the observed treatment initiation and the counterfactual CD4 under no
treatment initiation. The result of this computation was a 350 cells increase of CD4 after
1 year, a 362 cells increase after 2 years and an overall increase of 370 CD4 cells after an
infinite (large) time. Technical implementation details and code for analysis are described in
Web-Supplementary Material C.
Table 2 presents the estimates for Models 1-7 on the simulated datasets. (see detail in
Web-Supplementary Material A2 and A3). All results and conclusions are similar in small
and large samples. The naive Model 1 largely underestimated the treatment effect. This was
corrected by the MSM Models 2 and 3. Model 4 also yielded good estimates of the mean
causal effect in treated patients both for the first year and subsequent years. However, we
can notice that long-term increase of CD4 is infinite in Models 1 to 4. Models 5-7 exhibit an
equilibrium point which makes it possible to consider the long-term causal effect of treatment.
All dynamic models gave a correct estimate of the long-term effect of the treatment. The
initial increase in CD4 during the first year was not correctly caught by Model 5. Models
6 and 7 which both incorporate the dynamics of viral load gave a correct estimation of the
increase of CD4 count. Even if all models found a significant effect of treatment on CD4
counts in the first year, the Z-statistics for the no-effect hypothesis are larger for dynamical
models than for the GEE-based models, indicating more power to reject the null hypothesis.
Sandwich estimators were used for the standard errors (SE) for GEE method; adjusting for
uncertainty in the estimation of weights would lead to larger SE and thus would not impact
this conclusion.
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[Table 2 about here.]
4. Real data
We used two large cohorts: the ANRS CO3 Aquitaine cohort (Thie´baut et al., 2000) and the
Swiss HIV Cohort Study (SHCS) (Sterne et al., 2005; Gran et al., 2013). Similarly to Cole
et al. (2005), we took a sub-sample of patients who were alive, HIV positive, yet untreated
and under follow-up in April 1996 when HAART became available. All patients taking ARV
in mono- or bi-therapy instead of HAART were excluded. Once a patient was on any therapy,
we assumed he or she remained on it. For each of them, the follow-up begins with the first
visit after April 1996 and ends with 1) the last visit at which he or she was seen alive, 2) the
last visit before patient discontinued the study, or 3) April 2003, whichever comes first. Data
were supposed missing at random (MCAR); thus we deleted observations where either the
viral load or the CD4 count was missing. Patients with at least 2 observations were included.
See Web-Supplementary Material B1 for a more precise description. Finally, we considered
1591 patients the Aquitaine cohort and 1726 patients for the SHCS. Table 3 gives descriptive
statistics.
[Table 3 about here.]
Table 4 displays the results we obtained for the treatment effect on CD4 counts. The naive
Model 1, not correcting for treatment attribution, indicated a small and non-significant
increase of CD4 for SHCS cohort, and a significant negative effect for the Aquitaine Cohort;
this illustrates the need for correcting for treatment attribution. Models 2 and 3 have different
weights but show rather similar results, probably because treatment initiation was mainly
driven by observed CD4 count. Both models yielded a significant increase of CD4 counts
for one year of treatment and after one year. The one-year increase, however, was much
smaller for the Aquitaine cohort than for the SCHS. See Web-Supplementary Material
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B2 for a discussion of this result in relation with a possible practical violations of the
experimental treatment assumption Cole and Herna´n (2008). The results of the dynamical
models, especially Models 6 and 7, were more consistent between the two cohorts.
[Table 4 about here.]
Model 6 is interesting because it dissociates the effect of the treatment on CD4 count and
on viral load. The estimated treatment effect on CD4 count was small in both cohorts and
was non-significant effect for the Aquitaine cohort. In contrast, the effect on viral load was
highly significant in both cohorts. This is consistent with the type of action of antiretroviral
treatments: the increase of CD4 counts is essentially mediated by the decrease in viral
load, which is the direct effect of antiretroviral treatments. Such biological knowledge is
incorporated in Model 7, where the treatment acts on the infectivity parameter. In view of
the Z-statistics obtained by a Wald test of the hypothesis β = 0 in Equation (2.8), the power
obtained in Model 7 seems to be very high (this was confirmed by a likelihood ratio test).
Moreover, Model 7 gives an insight into the value of the biological birth and death rates of
cells during the infection (see Web-Supplementary Material B3 for details). The estimates
from the two data sets are rather consistent in the sense that they have the same order of
magnitude, although a formal comparison would show that several parameters are different.
Finally, a simple way to look at these results and to compare them, is to consider the mean
evolution of CD4 along time. Figure 2 represents the predicted CD4 counts with Models 1,
3, 6 and 7 for treated patients starting at baseline with CD4 count of 365 and a viral load
of 4.4 (which are approximately the mean values at treatment initiation in the cohorts).
For Models 1 to 3, these curves are deterministic, which is not the case for Models 4 to 7
that have random effects. For these latter models, we computed the mean predicted curves
depending on the value of the random effect, which have to be set to values compatible
with the baseline values of the biomarkers. In order to set them, in both case, we computed
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the equilibrium point of the system without treatment and solved the system of equations.
Figure 2 shows that the naive Model 1 badly under-estimated the effect. Both Models 1 and
3 are unstable, whereas Model 6 or the mechanistic Model 7 are more consistent between
the two studies and have equilibrium points.
[Figure 2 about here.]
5. Conclusion
This paper proposed four dynamic models for estimating the effect of HAART on CD4
counts and compared them to the naive regression model and two variants of previously
proposed MSM models. The naive regression model (Model 1) strongly underestimated the
effect of the treatment. The MSM models (Models 2 and 3) corrected this misleading result
but sometimes failed to reach significance or were unstable across studies. The discrete-time
dynamic models (Models 4, 5 and 6) gave rather good estimates and appear to have a higher
power, although they may sometimes be too rigid. All the discrete-time models can be easily
fitted with classical softwares. The continuous-time dynamic model (Model 7) gave good
results. Models 6 and 7, which jointly model CD4 and viral load gave the most consistent
results, with a richer interpretation since they take into account that the effect of HAART
on CD4 is mediated by viral load.
We have used a linear MSM with two slopes very similar to that proposed by Cole et al.
(2005). This model is adapted to represent the short term (few years) effect of treatment but
not the long-term effect because it tends to infinity. It would be possible to define an MSM
in which the effect would be bounded but this would be at the cost of additional non-linear
parametrization. Also it would be possible to use more recent methods such as the history
adjusted MSM (Petersen et al., 2007) but their need is mostly justified to study dynamic
treatment regimes whereas we assessed the effect of a static treatment regimes in this work.
In contrast most dynamical models (although not Model 4) have an equilibrium point. Also,
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a MSM could be assumed for the increment Zt rather than for Yt. Thus, the MSM approach
could complement the dynamic approach in the sense that less stringent assumptions would
be needed for causal inference. However, the dynamic models already do a good job and
the need to correct them (at the price of more complex procedure and loss of power) is
not obvious. In this paper we assumed MCAR observations for GEE which is justified by
a majority of administrative censoring. MAR observations can be treated by using IPTC
weights; see Web-Supplementary Material Section B4. The likelihood-based approach used
for the dynamic models is valid for MAR observations.
The mechanistic Model 7 directly incorporates biological knowledge. This leads to a more
powerful test for the parameter of interest. Moreover, it distinguishes the system living in
continuous time and observations taken at discrete times. One of the advantages of this
distinction is that we would be able to use all the data: with discrete-time models we must
have approximately equally-spaced observations, which rarely occurs in real observational
studies. The simulated data in the paper are obtained with a dynamic model, so one might
think that this favors dynamic models; however the true generation process comes itself from
a complex system. Also, the simulated model is much more complex than Models 4-7 which
are thus misspecified.
Finally, mechanistic models, once estimated, open the possibility of designing optimal (or
sub-optimal) control of the therapy, as has been proposed on simulations by Adams et al.
(2004) and Ernst et al. (2006), and also Prague et al. (2012). The issue of “optimal treatment
regime” has also been tackled outside of the context of mechanistic models (Petersen et al.,
2007; Orellana et al., 2010; Saarela et al., 2015). The drawback of the continuous-time
approach is that it is numerically challenging and requires special software running on cluster
computers.
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Web-Supplementary Materials
Web-Supplementary Material referenced in Sections 3, 4 and 5, the simulated data analyzed
in Section 3 and a R program implementing models 1-6 are available with this paper at
the Biometrics website on Wiley Online Library. Programs to estimate the parameters with
model 7 are available on a dedicated website: http://www.isped.u-bordeaux.fr/NIMROD.
Acknowledgement
The authors thank the investigators of the Aquitaine Cohort and the Swiss HIV Cohort
Study. Parallel computing was used thanks to the MCIA (Me´socentre de Calcul Intensif
Aquitain) of the Universite´ de Bordeaux and of the Universite´ de Pau et des Pays de l’Adour.
References
Aalen, O. (1987). Dynamic modelling and causality. Scandinavian Actuarial Journal 1987,
177–190.
Aalen, O., Røysland, K., Gran, J., and Ledergerber, B. (2012). Causality, mediation and
time: a dynamic viewpoint. Journal of the Royal Statistical Society: Series A (Statistics
in Society) 175, 831–861.
Adams, B., Banks, H., Davidian, M., Kwon, H., Tran, H., Wynne, S., and Rosenberg,
E. (2005). HIV dynamics: modeling, data analysis, and optimal treatment protocols.
Journal of Computational and Applied Mathematics 184, 10–49.
Adams, B., Banks, H., Kwon, H.-D., and Tran, H. T. (2004). Dynamic multidrug therapies
for hiv: Optimal and sti control approaches. Mathematical Biosciences and Engineering
1, 223–241.
Arjas, E. and Parner, J. (2004). Causal reasoning from longitudinal data*. Scandinavian
Journal of Statistics 31, 171–187.
Cole, S. and Herna´n, M. (2008). Constructing inverse probability weights for marginal
structural models. American journal of epidemiology 168, 656–664.
16 Biometrics, December 2015
Cole, S., Herna´n, M., Anastos, K., Jamieson, B., and Robins, J. (2007). Determining the
effect of highly active antiretroviral therapy on changes in human immunodeficiency virus
type 1 RNA viral load using a marginal structural left-censored mean model. American
journal of epidemiology 166, 219–227.
Cole, S., Herna´n, M., Margolick, J., Cohen, M., and Robins, J. (2005). Marginal structural
models for estimating the effect of highly active antiretroviral therapy initiation on CD4
cell count. American journal of epidemiology 162, 471–478.
Cole, S., Jacobson, L., Tien, P., Kingsley, L., Chmiel, J., and Anastos, K. (2010). Using
marginal structural measurement-error models to estimate the long-term effect of an-
tiretroviral therapy on incident AIDS or death. American journal of epidemiology 171,
113–122.
Commenges, D. and Ge´gout-Petit, A. (2009). A general dynamical statistical model with
causal interpretation. Journal of the Royal Statistical Society: Series B (Statistical
Methodology) 71, 719–736.
Commenges, D. and Ge´gout-Petit, A. (2015). The stochastic system approach for estimating
dynamic treatments effect. Lifetime Data Analysis submitted, –.
Commenges, D. and Jacqmin-Gadda, H. (2015). Dynamical Biostatistical Models. Chapman
& Hall.
Didelez, V. (2008). Graphical models for marked point processes based on local independence.
Journal of the Royal Statistical Society: Series B (Statistical Methodology) 70, 245–264.
Diggle, P., Farewell, D., and Henderson, R. (2007). Analysis of longitudinal data with drop-
out: objectives, assumptions and a proposal. Journal of the Royal Statistical Society:
Series C (Applied Statistics) 56, 499–550.
Eichler, M. and Didelez, V. (2010). On granger causality and the effect of interventions in
time series. Lifetime data analysis 16, 3–32.
Dynamic models for estimating the effect of HAART on CD4 in observational studies 17
Ernst, D., Stan, G.-B., Goncalves, J., and Wehenkel, L. (2006). Clinical data based optimal
sti strategies for hiv: a reinforcement learning approach. In Decision and Control, 2006
45th IEEE Conference on, pages 667–672. IEEE.
Ge´gout-Petit, A. and Commenges, D. (2010). A general definition of influence between
stochastic processes. Lifetime data analysis 16, 33–44.
Gran, J., Roysland, K., Ledergerber, B., Young, J., and Aalen, O. (2013). Analysing
time-dependent confounding by imputation of counterfactual covariate trajectories:
Application to data from the swiss HIV cohort study. Statistics in medecine -, submitted.
Granger, C. (1969). Investigating causal relations by econometric models and cross-spectral
methods. Econometrica: Journal of the Econometric Society 37, 424–438.
Guedj, J., Thie´baut, R., and Commenges, D. (2007). Maximum likelihood estimation in
dynamical models of HIV. Biometrics 63, 1198–1206.
Herna´n, M. a., Brumback, B., and Robins, J. (2002). Estimating the causal effect of
zidovudine on CD4 count with a marginal structural model for repeated measures.
Statistics in medicine 21, 1689–709.
Hoff, R., Gran, J., and Farewell, D. (2015). Farewell’s linear increments model for missing
data: The FLIM package. The R Journal -, To be published.
Hubbard, A., Ahern, J., Fleischer, N., Van der Laan, M., Lippman, S., Jewell, N., Bruckner,
T., and Satariano, W. (2010). To GEE or not to GEE: comparing population average
and mixed models for estimating the associations between neighborhood risk factors and
health. Epidemiology 21, 467–474.
Ko, H., Hogan, J. W., and Mayer, K. H. (2003). Estimating causal treatment effects from
longitudinal hiv natural history studies using marginal structural models. Biometrics
59, 152–162.
Lavielle, M., Samson, A., Karina Fermin, A., and Mentre´, F. (2011). Maximum likelihood
18 Biometrics, December 2015
estimation of long-term HIV dynamic models and antiviral response. Biometrics 67,
250–259.
Liang, K. and Zeger, S. (1986). Longitudinal data analysis using generalized linear models.
Biometrika 73, 13–22.
Orellana, L., Rotnitzky, A., and Robins, J. M. (2010). Dynamic regime marginal structural
mean models for estimation of optimal dynamic treatment regimes, part i: main content.
The International Journal of Biostatistics 6, ISSN 1557–4679.
Pepe, M. and Anderson, G. (1994). A cautionary note on inference for marginal regression
models with longitudinal data and general correlated response data. Communications
in Statistics-Simulation and Computation 23, 939–951.
Perelson, A. (2002). Modelling viral and immune system dynamics. Nature Reviews
Immunology 2, 28–36.
Petersen, M. L., Deeks, S. G., Martin, J. N., and van der Laan, M. J. (2007). History-adjusted
marginal structural models for estimating time-varying effect modification. American
journal of epidemiology 166, 985–993.
Petersen, M. L., Deeks, S. G., and van der Laan, M. J. (2007). Individualized treatment
rules: Generating candidate clinical trials. Statistics in medicine 26, 4578–4601.
Petersen, M. L., Wang, Y., van der Laan, M. J., and Bangsberg, D. R. (2006). Assessing the
effectiveness of antiretroviral adherence interventions: using marginal structural models
to replicate the findings of randomized controlled trials. JAIDS Journal of Acquired
Immune Deficiency Syndromes 43, S96–S103.
Prague, M., Commenges, D., Drylewicz, J., and Thie´baut, R. (2012). Treatment monitoring
of hiv-infected patients based on mechanistic models. Biometrics 68, 902–911.
Prague, M., Commenges, D., Guedj, J., Drylewicz, J., and Thie´baut, R. (2013). NIMROD:
a program for inference via a normal approximation of the posterior in models with
Dynamic models for estimating the effect of HAART on CD4 in observational studies 19
random effects based on ordinary differential equations. Computer methods and programs
in biomedicine 111, 447–458.
Prague, M., Commenges, D., and Thie´baut, R. (2013). Dynamical models of biomarkers and
clinical progression for personalized medicine: The HIV context. Advanced drug delivery
reviews 65, 954–965.
Robins, J., Herna´n, M., and Brumback, B. (2000). Marginal structural models and causal
inference in epidemiology. Epidemiology 11, 550–60.
Saarela, O., Stephens, D. A., Moodie, E. E., and Klein, M. B. (2015). On bayesian estimation
of marginal structural models. Biometrics 71, 279–288.
Sterne, J., Herna´n, M., Ledergerber, B., Tilling, K., Weber, R., Sendi, P., Rickenbach, M.,
Robins, J., and Egger, M. (2005). Long-term effectiveness of potent antiretroviral therapy
in preventing AIDS and death: a prospective cohort study. The Lancet 366, 378–384.
Thie´baut, R., Morlat, P., Jacqmin-Gadda, H., Neau, D., Mercie´, P., Dabis, F., Cheˆne, G., and
the Groupe d’Epidmiologie du SIDA en Aquitaine (GECSA) (2000). Clinical progression
of HIV-1 infection according to the viral response during the first year of antiretroviral
treatment. Aids 14, 971–978.
Walker, A. (1996). Confounding by indication. Epidemiology 7, 335–336.
Wu, H. (2005). Statistical methods for HIV dynamic studies in AIDS clinical trials. Statistical
Methods in Medical Research 14, 171–192.
APPENDIX: Correspondence between parameters of MSM and LIM
The question is difficult for two reasons: the models are constructed differently; the philo-
sophical approach to causality is different. We will make this exercise for comparing the MSM
Models 2-3 and the dynamic Model 4. One can reconcile the two philosophical approach by
saying that the “causal” interpretation (in a interventional point of view) is that, for a new
patient who will be given treatment trajectory a¯t, we expect under the MSM models 2-3:
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E(Yt(a¯t)|Y0) = β0 + β1cum(a¯t−1) + β2cumlag(a¯t−1) + β3t + β4Y0. Model 4 is formulated in
terms of the increments Z: Zt = α0 + α1At−1 + α2At−2 + b + εt, which by summation gives
Yt = Y0 +α1cum(A¯t−1)+α2cumlag(A¯t−1)+α3t+Mt, where Mt = b+
∑t
k=1 εt is a martingale.
This is the Doob decomposition of the process Y . With the assumption of a “perfect” system
or a NUC system (see Commenges and Ge´gout-Petit (2015) and Chapter 9 of Commenges and
Jacqmin-Gadda (2015)), if we apply treatment trajectory a¯t, this define a new probability P
a
under which the Doob decomposition is: Yt = Y0 +α1cum(a¯t−1)+α2cumlag(a¯t−1)+α3t+Mt,
from which we deduce: E(Yt|Y0) = Y0 +α1cum(a¯t−1) +α2cumlag(a¯t−1) +α3t. Thus, Model 4
yields the same expectation under an intervention imposing treatment trajectory a¯ as Models
2-3 if β4 = 1, and the parameters giving the effects of cum(a¯t−1) and cumlag(a¯t−1) correspond.
The way the model is estimated in the dynamic approach makes stronger assumptions than
the MSM. Essentially it assumes that there is no confounder between Z and A. That is,
there is no variable that influences both Zt and At−1. For instance the viral load Vt−1 might
be a confounder; such a confounder can be taken into account in the treatment model in
a MSM. However, this confounding effect is not major; moreover, complex dynamic models
(such as Model 6) can take viral load into account. For Models 5, 6 and 7, marginal effects
can still be computed (analytically or by simulation), but this may lead to complex forms,
while generally MSMs assume simple mathematical structures.
Received February 2015. Revised ??? ???. Accepted ??? ???.
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Figure 1: Mechanistic models for HIV dynamics. Type of cells of interest are viruses (V ),
effector cells E and CD4 cells which may be quiescent (Q), target cells (T , T1, T2) or infected
(T ∗, T ∗1 , T
∗
2 ). Parameters are defined in Table 1.
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Figure 2: Mean evolution of CD4 predicted by Model 1 (plain line, simple regression), Model
3 (dashed line, MSM), Model 6 dotted line, linear incremental system) and Model 7 (dashed-
dotted line, mechanistic model) for treated patients starting with 325 CD4 cells/mL and a
viral load of 3.9 log10 copies/mm3: (left) estimates from the SHCS data (right) estimates
from the Aquitaine cohort.
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Table 1: Meaning of parameters in the dynamical models presented in Figure 1. The upper
part gives prior means and standard deviations for normal a priori distributions used for
estimation of mechanistic parameters in Model 7 for the “Target cell model”. The lower part
gives parameter values used for data simulation from the Adams et al. (2005) model.
Normal priors used for analysis∗
on the log value of the parameter
Name Description mean sd.
λ Natural production rate cells
µL.day
2.55 1.90
µT∗ Natural death rate of T
∗ cells 1
day
-0.05 0.68
µQ Natural death rate of Q cells
1
day
-9.00 1.00
α Transition rates between Q and T cells 1
day
-4.00 2.00
ρ Transition rates between T and Q cells 1
day
-4.34 1.38
µT Virions natural death rate
1
day
-2.59 0.34
γ Infectivity parameter µL
day
-5.76 4.02
pi Rate of production of virions by infected cells 1
day
4.04 2.66
µV Natural death rate of T
∗ cells 1
day
2.83 0.68
Parameter Value used for simulations
for each population (X)†
Name Description Units Type 1 Type 2 Effectors Virus
λX Natural production rate
cells
mL.day
5000 31.98 1.0 -
(1-X) Treatment efficacy no unit 50% 83% - -
dX Natural death rate
1
day
0.01 0.01 0.25 -
δX Infection-induced death rate
1
day
0.7 0.7 0.1 -
ρX Number of virions infecting a cell
virions
cells
1 1 - -
mX Immune-induced clearance rate
mL
cells.day
1× 10−5 1× 10−5 - -
kX Infection rate
mL
virions.day
8× 10−7 1× 10−4 - -
c Virions natural death rate 1
day
- - - 13
NT Virions production per infected cells
virions
cells
- - - 100
Kb Saturation constant cells birth
cells
mL
- - 100 -
Kd Saturation constant cells death
cells
mL
- - 500 -
bE Infection-induced birth rate for E cells
1
day
- - 0.3 -
∗ Reference and explanation for these choices can be found in Prague et al. (2012).
†For each simulated patient, every parameter got a random effect leading to 50% coefficient of variation
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Table 2: Estimated treatment effect on CD4 counts from simulated data: Model 1: Naive
regression; Model 2: MSM with simple treatment model; Model 3: MSM with more complete
treatment model; Model 4: simple dynamic model; 5: autoregressive model; Model 6:
bivarariate dynamic model; Model 7: mechanistic model.
Simulated Dataset with Adams et al. (2005) model
n=200 n=1500
Model β treatment∗ Effect Sd. Z-stat† Effect Sd. Z-stat†
Model 1 < 1 yr 136 29 4.68 172 11 16.34
> 1 yr -11 43 -0.38 -12 16 -1.13
∞ −∞ - - −∞ - -
Model 2 < 1 yr 320 31 10.44 322 11 28.71
> 1 yr -15 46 -0.49 -8 17 -0.72
∞ −∞ - - −∞ - -
Model 3 < 1 yr 327 31 10.64 325 11 28.81
> 1 yr -14 46 -0.45 -7 17 -0.62
∞ −∞ - - −∞ - -
Model 4 < 1 yr 362 17 21.60 378 6 61.35
> 1 yr 8 24 0.33 7 9 0.8
∞ +∞ - - +∞ - -
Model 5 < 1 yr 133 - - 136 - -
> 1 yr 84 - - 86 - -
∞ 359 - - 370 - -
Param. 149 5 31.24 154 2 89.36
Model 6 < 1 yr 325 - - 334 - -
> 1 yr 31 - - 34 - -
∞ CD4 360 - - 371 - -
∞ VL -1.9 - - -2 - -
Param. CD4 600 21 28.42 630 8 82.22
Param. VL -7 0 -40.86 -7 0 -120.51
Model 7 < 1 yr 312 - - 304 - -
> 1 yr 2 - - 4 - -
∞ CD4 308 - - 306 - -
∞ VL -5.6 - - -4.98 - -
Param. γ -1.12 0.014 -79.3 -1.03 0.003 -295.6
†Estimates for treatment effect (β) are significant at level 10% if the absolute value of Z-stat is
greater than 1.64 and significant at level 5% if the absolute value of Z-stat is greater than 1.96.
∗ To be compared with mean treatment effect in treated for (< 1 year; > 1 year; ∞):
benchmarks values are (350;12;370) for these simulations.
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Table 3: Data description for illustrations : Average viral load, CD4 counts and percentage
of treatment attribution in the population are displayed for simulated data and real data
from the Aquitaine cohort and the SHCS. Statistics displayed are mean [Q1;Q3].
Simulated Aquitaine
dataset Cohort SHCS
n 200 1500 1591 1726
Missing data
Administrative - - 81.6% 74.7%
Death - - 12.7% 6.4%
Lost of follow-up - - 5.7% 18.9%
CD4 count
Baseline 428 [ 266 ; 545 ] 420 [ 253 ; 530 ] 471 [ 298 ; 612 ] 536 [ 357 ; 670 ]
Follow-up untreated 594 [ 485 ; 675 ] 588 [ 478 ; 656 ] 625 [ 440 ; 762 ] 543 [ 363 ; 675 ]
Follow-up treated 627 [ 417 ; 837 ] 606 [ 405 ; 801 ] 492 [ 315 ; 638 ] 507 [ 300 ; 660 ]
Viral Load
Baseline 3.9 [ 3.3 ; 4.6 ] 4 [ 3.4 ; 4.7 ] 4.2 [ 3.6 ; 4.8 ] 4.0 [ 3.4 ; 4.6 ]
Follow-up untreated 3.5 [ 2.9 ; 4.2 ] 3.7 [ 3.1 ; 4.4 ] 3.3 [ 2.3 ; 4.2 ] 3.8 [ 3.1 ; 4.5 ]
Follow-up treated 2.6 [ 1.7 ; 3.2 ] 2.6 [ 1.7 ; 3.2 ] 2.7 [ 1.7 ; 3.6 ] 3.2 [ 2.4 ; 4.1 ]
% undetectable viral load (3%;4%;40%) (2%;3%;38%) (7%;22%;48%) (10%;15%;57%)
(baseline,untreated, treated)
Treatment attribution
Time (day) 412 [ 1 ; 631 ] 377 [ 91 ; 451 ] 727 [ 1 ; 1281 ] 548 [ 183 ; 752 ]
% treated 69% 65% 64% 34%
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Table 4: Estimated treatment effect on CD4 counts from real data of the Aquitaine cohort
and SHCS: Model 1: Naive regression; Model 2: MSM with simple treatment model;
Model 3: MSM with more complete treatment model; Model 4: simple dynamic model; 5:
autoregressive model; Model 6: bivarariate dynamic model; Model 7: mechanistic model.
Real Dataset observational studies
SHCS Aquitaine Cohort
Model β treatment Effect Sd. Z-stat† Effect Sd. Z-stat†
Model 1 < 1 yr 6 16 0.34 -94 12 -7.55
> 1 yr 30 6 5.42 30 3 9.75
∞ +∞ - - +∞ - -
Model 2 < 1 yr 206 18 11.47 59 15 3.87
> 1 yr 54 8 6.67 41 5 8.03
∞ +∞ - - +∞ - -
Model 3 < 1 yr 208 18 11.31 36 20 1.87
> 1 yr 50 9 5.79 53 5 9.62
∞ +∞ - - +∞ - -
Model 4 < 1 yr 189 11 17.33 109 9 12.03
> 1 yr 73 16 4.54 55 13 4.28
∞ +∞ - - +∞ - -
Model 5 < 1 yr 26 - - 45 - -
> 1 yr 14 - - 19 - -
∞ 55 - - 79 - -
Param. 60 4 16.04 14 3 4.12
Model 6 < 1 yr 73 - - 92 - -
> 1 yr 26 - - 16 - -
∞ CD4 104 - - 111 - -
∞ VL -2.0 - - -2.3 - -
Param. CD4 80 16 5 28 18 1.53
Param. VL -3.29 0.09 -38.4 -3.19 0.1 -30.55
Model 7 < 1 yr 104 - - 71 - -
> 1 yr 18 - - 9 - -
∞ CD4 127 - - 86 - -
∞ VL -4.09 - - -3.14 - -
Param. γ -1.73 0.05 -34.79 -0.89 0.01 -85.77
†Estimates for treatment effect (β) are significant at level 10% if the Z-stat is greater than 1.64
and significant at level 5% if the Z-stat is greater than 1.96.
